szmtag Autosomal Dominant Polycystic Kidney Disease (02.11.2007)
DÄ internationalArchive44/2007Autosomal Dominant Polycystic Kidney Disease

Review article

Autosomal Dominant Polycystic Kidney Disease

Dtsch Arztebl 2007; 104(44): A-3022

Kühn, W; Walz, G

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Guay-Woodford LM: Renal cystic diseases: diverse phenotypes converge on the cilium/centrosome complex. Pediatr Nephrol 2006; 21: 1369–76. MEDLINE
2. Bergmann C, Frank V, Kupper F, Kamitz D, Hanten J, Berges P et al.: Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease. Mol Diagn Ther 2006; 10: 163–74. MEDLINE
3. Saunier S, Salomon R, Antignac C: Nephronophthisis. Curr Opin Genet Dev 2005; 15: 324–31. MEDLINE
4. Wilson PD: Polycystic kidney disease. N Engl J Med 2004; 350: 151–64. MEDLINE
5. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr. et al.: Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122–30. MEDLINE
6. Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, Brown RD Jr., Piepgras DG et al.: Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362: 103–10. MEDLINE
7. Hop JW, Rinkel GJ, Algra A, van Gijn J: Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997; 28: 660–4. MEDLINE
8. Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT et al.: Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol 2006; 17: 854–62. MEDLINE
9. Gibson P, Watson ML: Cyst infection in polycystic kidney disease: a clinical challenge. Nephrol Dial Transplant 1998; 13: 2455–7. MEDLINE
10. Bajwa ZH, Gupta S, Warfield CA, Steinman TI: Pain management in polycystic kidney disease. Kidney Int 2001; 60: 1631–44. MEDLINE
11. Elles RG, Hodgkinson KA, Mallick NP, O'Donoghue DJ, Read AP, Rimmer S et al.: Diagnosis of adult polycystic kidney disease by genetic markers and ultrasonographic imaging in a voluntary family register. J Med Genet 1994; 31: 115–20. MEDLINE
12. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM et al.: Von Hippel-Lindau disease. Lancet 2003; 361: 2059–67. MEDLINE
13. Henske EP: Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol 2005; 20: 854–7. MEDLINE
14. Hildebrandt F, Omram H: New insights: nephronophthisis-medullary cystic kidney disease. Pediatr Nephrol 2001; 16: 168–76. MEDLINE
15. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995; 81: 289–98. MEDLINE
16. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ et al.: PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272: 1339–42. MEDLINE
17. Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X et al.: Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 1997; 17: 179–81. MEDLINE
18. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM et al.: Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 1998; 93: 177–88. MEDLINE
19. Qian F, Watnick TJ, Onuchic LF, Germino GG: The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996; 87: 979–87. MEDLINE
20. Pazour GJ: Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004; 15: 2528–36. MEDLINE
21. Yoder BK, Richards WG, Sweeney WE, Wilkinson JE, Avener ED, Woychik RP: Insertional mutagenesis and molecular analysis of a new gene associated with polycystic kidney disease. Proc Assoc Am Physicians 1995; 107: 314–23. MEDLINE
22. Praetorius HA, Spring KR: A physiological view of the primary cilium. Annu Rev Physiol 2005; 67: 515–29. MEDLINE
23. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323–6. MEDLINE
24. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46–51. MEDLINE
25. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N et al.: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466–71. MEDLINE
e1. Brisman JL, Song JK, Newell DW: Cerebral aneurysms. N Engl J Med 2006; 355: 928–39. MEDLINE
e2. Torra R, Nicolau C, Badenas C, Bru C, Perez L, Estivill X et al.: Abdominal aortic aneurysms and autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1996; 7: 2483–6. MEDLINE
e3. Lumiaho A, Ikaheimo R, Miettinen R, Niemitukia L, Laitinen T, Rantala A et al.: Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 2001; 38: 1208–16. MEDLINE
e4. Dominguez Fernandez E, Albrecht KH, Heemann U, Kohnle M, Erhard J, Stoblen F et al.: Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease. Transpl Int 1998; 11: 28–31. MEDLINE
e5. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT: Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990; 11: 1033–7. MEDLINE
e6. Kirchner GI, Rifai K, Cantz T, Nashan B, Terkamp C, Becker T et al.: Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 2006; 12: 1268–77. MEDLINE
e7. Ritz E: Hypertension in autosomal dominant polycystic kidney disease: is renin acquitted as a culprit? J Hypertens 2006; 24: 1023–5. MEDLINE
e8. Bajwa ZH, Sial KA, Malik AB, Steinman TI: Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66: 1561–9. MEDLINE
e9. Badani KK, Hemal AK, Menon M: Autosomal dominant polycystic kidney disease and pain – a review of the disease from aetiology, evaluation, past surgical treatment options to current practice. J Postgrad Med 2004; 50: 222–6. MEDLINE
e10. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB et al.: Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2006; 17: 3013–9. MEDLINE
e11. Rossetti S, Chauveau D, Walker D, Saggar-Malik A, Winearls CG, Torres VE et al.: A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int 2002; 61: 1588–99. MEDLINE
e12. Zerres K, Rudnik-Schoneborn S, Senderek J, Eggermann T, Bergmann C: Autosomal recessive polycystic kidney disease (ARPKD). J Nephrol 2003; 16: 453–8. MEDLINE
e13. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994; 77: 881–94. MEDLINE
e14. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millan JL et al.: The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 1995; 10: 151–60. MEDLINE
e15. Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG: PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 1997; 16: 179–83. MEDLINE
e16. Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G: Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci USA 1997; 94: 6965–70. MEDLINE
e17. Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R et al.: Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 2002; 18: 18. MEDLINE
e18. Lu W, Fan X, Basora N, Babakhanlou H, Law T, Rifai N et al.: Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes [letter]. Nat Genet 1999; 21: 160–1. MEDLINE
e19. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout MA: Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci U S A 2000; 97: 1731–6. MEDLINE
e20. Wu G, Markowitz GS, Li L, D'Agati VD, Factor SM, Geng L et al.: Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 2000; 24: 75–8. MEDLINE
e21. Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, Sandford R: Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci U S A 2001; 98: 12174–9. MEDLINE
e22. Kotsis F, Nitschke R, Boehlke C, Bashkurov M, Walz G, Kuehn EW: Ciliary calcium signaling is modulated by kidney injury molecule-1 (Kim1). Pflugers Arch 2007; 453: 819–29. MEDLINE
e23. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X et al.: Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33: 129–37. MEDLINE
e24. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363–4. MEDLINE
e25. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598–604. MEDLINE
e26. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006; 124: 471–84. MEDLINE
e27. Pirson Y, Chauveau D, Torres V: Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2002; 13: 269–76. MEDLINE